An interventional study of Meal test taking and hormones measure including 26RFa in Diabetes and Obesity, sponsored by University Hospital, Rouen. Completed at 1 site in France. Open to female participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Basic science
The 26RFa was recently discovered in the hypothalamus. In rodents it seems to be related to glucose metabolism and obesity. However, no data exists in obese patients or in patients with diabetes. Thus, the investigators planned to dose 26RFa level in obese patients before and after a sleeve gastrectomy in order to study the effect of a weight loss on its levels. The investigators will also dose 26RFa concentrations in obese patients with type 2 diabetes and in healthy volunteers with normal weight. Comparison of these different groups will permit us to better understand the 26RFa involvement in glucose concentration regulation and in obesity.
The 26RFa is an orexigenic neuropeptide of the Rfamides family, localized in two hypothalamic nuclei. Its increase induced obesity and it is elevated in obese rodents. In addition, in human, it is elevated in anorexic patients. However, no data exists in obese patients or in patients with diabetes. Thus, the investigators planned to measure 26RFa level in obese patients before and after a sleeve gastrectomy in order to study the effect of a weight loss on its levels. The investigators will also dose 26RFa concentrations in obese patients with type 2 diabetes and in healthy volunteers with normal weight. Comparison of these different groups will permit us to better understand the 26RFa involvement in glucose concentration regulation and in obesity.
The investigators will also measure other hormones known to have a major role in glucose metabolism and obesity (ie. insulin, adiponectin).
A meal test will be given to the volunteers in order to study the kinetics' of these molecules during and after food intake.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 62 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →University Hospital, Rouen is the lead sponsor of 410 studies on the registry; 104 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients :
Inclusion Criteria:
Exclusion Criteria:
Healthy volunteers :
Inclusion Criteria:
Exclusion Criteria:
Meal test taking and hormones measure including 26RFa
Behavioral: Meal test taking and hormones measure including 26RFa
Meal test taking and hormones measure including 26RFa
Behavioral: Meal test taking and hormones measure including 26RFa
Meal test taking and hormones measure including 26RFa
Behavioral: Meal test taking and hormones measure including 26RFa
Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
Serum 26RFa levels
Serum 26RFa levels will be measured in fasting conditions before a sleeve gastrectomy in obese patients with or without diabetes.
Time frame: About 1 month before a sleeve gastrectomy
Kinetics of 26RFa levels during a test meal
levels of 26RFa levels will be measured during a meal test before and after a sleeve gastrectomy in obese patients with or without diabetes, and once a time in healthy volunteers.
Time frame: Before (about 1 month) and after a sleeve gastrectomy (D30 and D180), during a test meal (T0, T30, T60, T90, T120, T150 and T180 )
kinetics of classical hormones implicated in glucose control and obesity
levels of classical hormones implicated in glucose control and obesity will be measured during a meal test before and after a sleeve gastrectomy in obese patients with or without diabetes, and once a time in healthy volunteers.
Time frame: Before (about 1 month) and after a sleeve gastrectomy (D30 and D180), during a test meal (T0, T30, T60, T90, T120, T150 and T180 )
Levels of 26RFa and classical hormones implicated in glucose control and obesity just after a sleeve gastrectomy
Levels of 26RFa and classical hormones implicated in glucose control and obesity just after a sleeve gastrectomy (D3) in obese patients with or without diabetes.
Time frame: at D3 after a sleeve gastrectomy
score of satiety
Score satiety will be calculated using a questionary before and after a sleeve gastrectomy : once a time at D3, and at T0, T90 and T180 during a meal test at D30 and D180, in obese patients with or without diabetes. It will be also calculated in healthy volunteers at T0, T90 and T180 during a test meal.
Time frame: Before (about 1 month) and after a sleeve gastrectomy (D3, D30 and D180)
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Rouen